Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study

Figure 2 Outcomes after 12 months of treatment with early and late administration of rituximab BCD020 biosimilar. A: Dynamics of corticosteroids; B: Dynamics of Systemic Lupus Erythematosus Disease Activity Index. ERA: Early rituximab administration; LRA: Late rituximab administration.